Kalbe Farma stock at EUR 0.04 with IDR 34.6 trillion market cap

Published on 10/12/2026 at 13:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kalbe Farma stock costs EUR 0.04 on October 12, 2026 against a EUR 0.03 bid. Its market value was IDR 34.6 trillion.

Key points in brief

Kalbe Farma stock was at EUR 0.04 at Lang & Schwarz on October 12, 2026 at 1:36 p.m. CEST.
The company had an IDR 34.6 trillion market capitalization and an IDR 630.00 to IDR 1,345.00 52-week range.
Second-quarter 2026 revenue was IDR 9.8 trillion and net income was IDR 890.5 billion.
Seventeen analysts tracked by Investing.com had an average 12-month target of IDR 1,131.00.

Kalbe Farma, ID1000125107, Illustration mit AI erstellt.

Kalbe Farma stock (ISIN ID1000125107) was at EUR 0.04 at Lang & Schwarz on October 12, 2026 at 1:36 p.m. CEST, with a EUR 0.03 bid and EUR 0.05 ask. Its IDX-listed parent carried a market capitalization of IDR 34.6 trillion, giving the small euro quotation a clear valuation context.

Price sits in a wide range

The primary listing is Kalbe Farma on the Indonesia Stock Exchange under ticker KLBF, as identified by 6ix. The IDR 630.00 to IDR 1,345.00 52-week range places the IDR 765.00 home-market quote well above the annual low and below the annual high on October 12, 2026.

Trading conditions were thin in the German quotation. Lang & Schwarz showed a EUR 0.04 price, while the bid and ask spread ran from EUR 0.03 to EUR 0.05. For German investors, that spread is material because it is larger than the quoted share price increment itself.

Revenue grows, profit contracts

Kalbe Farma generated IDR 9.8 trillion of revenue and IDR 890.5 billion of net income in the second quarter of 2026, according to Investing.com. Revenue increased from IDR 9.7 trillion in the first quarter, while net income fell from IDR 1.0 trillion, making margin development more important than sales growth alone.

For the first half of 2026, Kontan reported revenue of IDR 19.48 trillion, up 14.05 percent year over year, while net income declined 2.74 percent to IDR 1.97 trillion. Gross profit margin fell to 37.56 percent from 41.14 percent in the comparable period, a quantified counterweight to the top-line increase.

Comparison with peers

Kalbe Farma: , P/E 9.61, market capitalization IDR 34.6 trillion
PT Industri Jamu dan Farmasi Sido Muncul Tbk (IDX, IDR): minus 0.56 percent, P/E 10.76, market capitalization IDR 10.4 trillion
PT Tempo Scan Pacific Tbk (IDX, IDR): minus 1.14 percent, P/E 7.93, market capitalization IDR 11.7 trillion

Analyst targets remain higher

Investing.com listed 17 analyst ratings, including 15 Buy ratings and 2 Holds, with an average 12-month target of IDR 1,131.00. The same page showed a target range of IDR 820.00 to IDR 1,700.00, while the latest Jakarta quote was IDR 765.00, creating a wide spread between the low estimate and the upper case.

The central market question is therefore valuation versus execution. Kalbe Farma combines 14.05 percent first-half revenue growth with a 2.74 percent net-income decline, while its P/E of 9.61 remains below the wider target range cited by the analyst survey.

German quote remains tightly spread

At Lang & Schwarz, Kalbe Farma stock stood at EUR 0.04 on October 12, 2026 at 1:36 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Kalbe Farma stock.